The Postoperative Nausea and Vomiting (PONV) Management Market is estimated to be valued at USD 1.5 billion in 2025 and is projected to reach USD 5.0 billion by 2035, registering a compound annual growth rate (CAGR) of 12.8% over the forecast period.
-management-market-market-value-analysis.webp "Postoperative Nausea And Vomiting (ponv) Management Market Market Value Analysis")
| Metric | Value |
|---|---|
| Postoperative Nausea and Vomiting (PONV) Management Market Estimated Value in (2025 E) | USD 1.5 billion |
| Postoperative Nausea and Vomiting (PONV) Management Market Forecast Value in (2035 F) | USD 5.0 billion |
| Forecast CAGR (2025 to 2035) | 12.8% |
The postoperative nausea and vomiting management market is experiencing consistent growth driven by the increasing volume of surgical procedures, higher prevalence of risk factors such as obesity and opioid use, and heightened focus on improving patient recovery outcomes. Rising hospital admissions and the expansion of day care surgical centers have further supported demand for effective antiemetic therapies.
Continuous innovation in drug formulations and combination therapies is enhancing clinical outcomes while minimizing side effects. Healthcare providers are prioritizing evidence based protocols that improve patient comfort and reduce the length of hospital stays, thereby reinforcing the use of targeted treatments.
The outlook for this market remains positive as advances in personalized medicine and improved delivery mechanisms are anticipated to strengthen adoption across both inpatient and outpatient surgical settings.
-management-market-analysis-by-treatment-type.webp "Postoperative Nausea And Vomiting (ponv) Management Market Analysis By Treatment Type")
The serotonin antagonists segment is expected to account for 37.80% of the total market revenue by 2025, making it the leading treatment type. This growth is driven by the strong efficacy of serotonin receptor blockers in preventing nausea and vomiting in postoperative patients, particularly those receiving opioid based anesthesia.
Their favorable safety profile and broad clinical acceptance have supported their inclusion in standard prophylaxis protocols across surgical specialties.
The ability of serotonin antagonists to provide consistent symptom control and reduce the need for rescue medication has reinforced their adoption as the primary therapeutic choice in PONV management.
-management-market-analysis-by-distribution-channel.webp "Postoperative Nausea And Vomiting (ponv) Management Market Analysis By Distribution Channel")
The hospital pharmacies segment is projected to hold 49.20% of the overall market revenue by 2025, positioning it as the dominant distribution channel. This is attributed to the high volume of drug dispensing occurring directly at hospitals where surgeries are performed, ensuring immediate access to antiemetic medications during perioperative care.
The integration of hospital pharmacies with surgical departments allows for streamlined supply chain management, precise dosing, and adherence to clinical protocols.
Furthermore, the growing focus on patient centric care within hospital environments has strengthened the reliance on in house pharmacies for timely and controlled drug availability, solidifying their leading share in this market.
According to market research and competitive intelligence provider Future Market Insights- the market for Postoperative nausea and vomiting (PONV) management reflected a value of 7.4% during the historical period, 2020 to 2025.
The PONV management market has been growing steadily in recent years due to several factors, including an increasing number of surgeries being performed worldwide, growing awareness of the importance of PONV management for patient comfort and safety, and the development of new and effective antiemetic medications.
Several factors are driving the growth of the PONV management market, including the increasing prevalence of PONV, the development of new and effective antiemetic medications, and the adoption of non-pharmacological approaches to PONV management.
Thus, the market for postoperative nausea and vomiting (PONV) management is expected to register a CAGR of 12.8% in the forecast period 2025 to 2035.
Increasing number of surgeries driving growth of PONV market
The growing number of surgeries being performed globally is a key driver of the PONV management market. As the number of surgeries increases, the incidence of PONV also rises, leading to a greater demand for effective PONV management solutions.
The development of new and more effective antiemetic medications is another important driver of the PONV management market. These medications can provide better control of PONV symptoms, resulting in improved patient outcomes and satisfaction.
Healthcare providers are increasingly aware of the importance of managing PONV for patient comfort and safety. This has LED to greater adoption of PONV management protocols and the use of a range of pharmacological and non-pharmacological interventions.
The development of new technologies, such as electronic stimulation devices, has expanded the range of PONV management solutions available to healthcare providers. These technologies provide non-pharmacological options that can be used in conjunction with antiemetic medications to improve PONV management outcomes.
Pharmacological Interventions
Antiemetic Medications: Antiemetic medications are the most commonly used pharmacological intervention for PONV management. These medications work by blocking specific receptors in the brain that are responsible for inducing nausea and vomiting. Some of the commonly used antiemetic medications include ondansetron, dexamethasone, and metoclopramide.
Anesthetic Technique: The choice of anesthetic technique used during surgery can also impact the incidence of PONV. Regional anesthesia, such as spinal or epidural anesthesia, has been shown to be associated with a lower incidence of PONV compared to general anesthesia.
Non-Pharmacological Interventions
Acupuncture: Acupuncture involves the insertion of fine needles into specific points on the body to stimulate nerve pathways and promote healing. It has been shown to be effective in reducing the incidence of PONV.
Acupressure: Acupressure involves the application of pressure to specific points on the body to stimulate nerve pathways and promote healing. It has been shown to be effective in reducing the incidence of PONV.
Transcutaneous Electrical Nerve Stimulation (TENS): TENS involves the use of small electrical currents to stimulate nerve pathways and promote healing. It has been shown to be effective in reducing the incidence of PONV.
Side effects of antiemetics and expensive nature of PONV management hampering market growth
Patients vary widely in their susceptibility to PONV, and it can be difficult to predict who will experience it. This variability makes it challenging for healthcare providers to tailor treatments to individual patients.
Antiemetic medications are commonly used to manage PONV, but they can have side effects such as sedation, dizziness, and dry mouth. These side effects can be particularly problematic for patients who are already recovering from surgery.
Antiemetic medications can be expensive, and their cost can be a barrier to access for some patients. This can limit the ability of healthcare providers to provide effective PONV management. There is a lack of standardization in the management of PONV, with different healthcare providers using different protocols and medications. This can lead to inconsistency in care and can make it difficult to compare outcomes across different facilities.
Prevention is key to managing PONV, but it can be challenging to identify patients who are at high risk and to implement appropriate preventive measures. This can result in a higher incidence of PONV and increased costs associated with treatment. Some patients and healthcare providers may not be aware of the risks associated with PONV, or may not take it seriously enough. This can lead to inadequate management and can result in unnecessary suffering for patients.
-management-market-cagr-analysis-by-country.webp "Postoperative Nausea And Vomiting (ponv) Management Market Cagr Analysis By Country")
Increasing number of surgeries performed in the region boosting market growth
The North America postoperative nausea and vomiting (PONV) management market is a significant segment of the global PONV management market. North America comprises of developed countries such as the United States and Canada, which have well-established healthcare systems and advanced medical technologies.
The market growth can be attributed to factors such as the increasing number of surgical procedures, rising geriatric population, and the growing prevalence of PONV. The United States dominates the North America PONV management market due to the presence of a large number of hospitals, advanced healthcare infrastructure, and high healthcare expenditure.
According to the Centers for Disease Control and Prevention (CDC), there were around 0.8 Billion surgeries performed in the United States in 2020, which is expected to increase in the coming years. This high number of surgeries creates a significant demand for PONV management products and services.
The major players in the North America PONV management market include Acacia Pharma Group plc, Heron Therapeutics, Inc., Merck & Co., Inc., Eisai Co., Ltd., and GlaxoSmithKline plc. These companies are focused on developing innovative products and technologies to improve PONV management, which is expected to drive market growth in the region. Thus, North America is expected to possess 47% market share for PONV management market in 2025.
-management-market-europe-country-market-share-analysis,-2025-&-2035.webp "Postoperative Nausea And Vomiting (ponv) Management Market Europe Country Market Share Analysis, 2025 & 2035")
Technological advancements creating lucrative opportunities for PONV management in Europe
PONV is a common complication of surgery and affects a significant proportion of patients. According to a study published in the European Journal of Anaesthesiology, the incidence of PONV in Europe ranges from 10% to 80% depending on the type of surgery and patient characteristics. The increasing prevalence of PONV is driving the demand for effective PONV management products and services.
The number of surgical procedures performed in Europe is increasing, driven by factors such as the aging population, changing lifestyles, and advancements in medical technology. This creates a significant demand for PONV management products and services.
There have been significant technological advancements in the field of PONV management, such as the development of new antiemetic drugs and the use of non-pharmacological interventions such as acupuncture and acupressure. These advancements are improving the effectiveness of PONV management and are driving market growth.
Governments in Europe are taking initiatives to improve the quality of healthcare and reduce the burden of postoperative complications such as PONV. For example, the European Society of Anaesthesiology has published guidelines for the management of PONV, which are expected to improve the quality of care and drive market growth.
There is growing awareness among patients and healthcare providers about the risks associated with PONV and the importance of effective management. This is driving demand for PONV management products and services. Thus, Europe is expected to possess 43% market share for PONV management market in 2025.
Timely administration favoring growth of hospital pharmacies for PONV management
Hospital pharmacies have direct access to a wide range of antiemetic medications that are commonly used for PONV management. This allows healthcare providers to quickly obtain the appropriate medications for patients who are experiencing PONV.
Hospital pharmacists are highly trained professionals who have a thorough understanding of medication management, including the appropriate use of antiemetics. They can provide guidance on medication selection, dosing, and potential drug interactions, which is essential for effective PONV management.
PONV can occur rapidly and may require immediate intervention. Hospital pharmacies are often located within the hospital or adjacent to the surgical suite, which allows for timely administration of antiemetic medications as needed. In addition to medications, hospital pharmacies may have access to specialized equipment such as intravenous pumps, which can be used for the administration of antiemetic medications.
Compliance with regulations: Hospital pharmacies are subject to strict regulatory requirements, which ensures that medications are stored, dispensed, and administered in a safe and appropriate manner. This is particularly important for PONV management, as many antiemetic medications have the potential for adverse effects. Thus, hospital pharmacies are expected to possess 49% market share for PONV management market in 2025.
-management-market-analysis-by-company.webp "Postoperative Nausea And Vomiting (ponv) Management Market Analysis By Company")
Key players in the postoperative nausea and vomiting (PONV) management market are Acacia Pharma, Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc, Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, Merck and Co., GlaxoSmithKline Corporation
| Report Attribute | Details |
|---|---|
| Market Value in 2025 | USD 1.17 Billion |
| Market Value in 2035 | USD 3.9 Billion |
| Growth Rate | CAGR of 12.8% from 2025 to 2035 |
| Base Year for Estimation | 2025 |
| Historical Data | 2020 to 2025 |
| Forecast Period | 2025 to 2035 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2025 to 2035 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Treatment Type, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Rest of Latin America, Germany, United kingdom, France, Spain, Italy, Rest of Europe, India, Malaysia, Singapore, Thailand, Rest of South Asia, China, Japan, South Korea, Austria, New Zealand, GCC countries, South Africa, Israel, Rest of MEA |
| Key Companies Profiled | Acacia Pharma; Hoffmann-La Roche AG; Novartis AG; Ani Pharmaceuticals, Inc; Camurus AB; Sanofi S.A.; Helsinn Holding S.A.; Eisai Corporation; Merck and Co.; GlaxoSmithKline Corporation |
| Customization | Available Upon Request |
The global postoperative nausea and vomiting (PONV) management market is estimated to be valued at USD 1.5 billion in 2025.
The market size for the postoperative nausea and vomiting (PONV) management market is projected to reach USD 5.0 billion by 2035.
The postoperative nausea and vomiting (PONV) management market is expected to grow at a 12.8% CAGR between 2025 and 2035.
The key product types in postoperative nausea and vomiting (PONV) management market are serotonin antagonists, steroids, dopamine antagonists, neurokinin nk-1 receptor antagonists and non-pharmacological treatment.
In terms of distribution channel, hospital pharmacies segment to command 49.2% share in the postoperative nausea and vomiting (PONV) management market in 2025.
Explore Similar Insights
Postoperative Nausea and Vomiting (PONV) Management Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Chat With
MaRIA
